Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Immune system disorders – page 115

  • 1 641 clinical trials
  • 555 recruiting
  • 290 conditions
  • 28 countries

Conditions in this area

290 conditions with trials, the busiest first

Colitis ulcerative120Crohn's disease94Asthma88Dermatitis atopic88HIV infection75Rheumatoid arthritis75Systemic lupus erythematosus61Multiple sclerosis59Psoriasis53Psoriatic arthropathy46Myasthenia gravis43Systemic scleroderma39Type 1 diabetes mellitus38Conjunctivitis allergic34Idiopathic pulmonary fibrosis34Cardiac amyloidosis29Sjogren's syndrome29Interstitial lung disease28Immune thrombocytopenia27Endocrine ophthalmopathy26IgA nephropathy23Vitiligo23Hereditary angioedema22Axial spondyloarthritis21+266

Clinical trials in Immune system disorders

1 641 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 641 clinical trials

Juvenile idiopathic arthritis

Not recruiting

Study on the Effectiveness of Triamcinolone Hexacetonide Injections for Juvenile Idiopathic Arthritis in Patients Starting TNF Inhibitor Treatment

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:0–17 years
  • Substances:Triamcinolone Hexacetonide
  • Sponsor:Oslo University Hospital HF

Lupus nephritis

Not recruiting

Study on Anifrolumab for Adults with Active Lupus Nephritis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Anifrolumab
  • Sponsor:AstraZeneca AB

Conjunctivitis allergic

Not recruiting

Study on the Safety and Effectiveness of Betula Pollen Extract for Children and Adolescents Aged 5-17 with Birch Pollen Allergies and Possible Asthma

Registered drug
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Betula Pollen Extract
  • Sponsor:Stallergenes

Lupus nephritis+1

Not recruiting

Study on Vemircopan for Adults with Lupus Nephritis or IgA Nephropathy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Vemircopan
  • Sponsor:Alexion Pharmaceuticals Inc.

Idiopathic pulmonary fibrosis

Not recruiting

Study on the Effects of Deupirfenidone and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Deupirfenidone
  • Sponsor:Puretech Lyt 100 Inc.

Rheumatoid arthritis

Not recruiting

Study on the Effects of Baricitinib in Early-Stage Rheumatoid Arthritis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Baricitinib
  • Sponsor:Universitaetsklinikum Erlangen AöR

Axial spondyloarthritis

Not recruiting

Study of Secukinumab for Maintaining Remission in Patients with Non-Radiographic Axial Spondyloarthritis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Secukinumab
  • Sponsor:Novartis Pharma AG

Rheumatoid arthritis

Not recruiting

Study on Monitoring Adalimumab for Maintaining Disease Control in Adults with Rheumatoid Arthritis

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:Adalimumab
  • Sponsor:Diakonhjemmet Sykehus AS

Rheumatoid arthritis

Not recruiting

Study on the Effects of Folate-Based Liposomes with Methotrexate for Patients with Moderate-to-Severe Rheumatoid Arthritis

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Methotrexate
  • Sponsor:Solfarcos Solucoes Farmaceuticas E Cosmeticas Lda.

Colitis ulcerative+1

Not recruiting

Study on the Effectiveness and Safety of Subcutaneous Infliximab for Patients with Active Crohn's Disease or Ulcerative Colitis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Infliximab
  • Sponsor:Centre Medico Chirurgical Ambroise Pare Hartmann

Systemic lupus erythematosus+1

Not recruiting

Study on the Safety and Effects of YTB323, Fludarabine Phosphate, and Tocilizumab in Patients with Severe, Refractory Systemic Lupus Erythematosus

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Novartis Pharma AG

Idiopathic pulmonary fibrosis

Not recruiting

Study on Fipaxalparant for Patients with Idiopathic Pulmonary Fibrosis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fipaxalparant
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Substances studied in this area

The therapies tested most often in Immune system disorders trials.

Sodium Chloride61 clinical trialsRituximab50 clinical trialsPrednisone47 clinical trialsAdalimumab40 clinical trialsEmtricitabine39 clinical trialsTocilizumab38 clinical trialsTenofovir Alafenamide37 clinical trialsMethotrexate36 clinical trialsPrednisolone35 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.